By Robert Reich –
According to a new federal database put online last week, pharmaceutical companies and device makers paid doctors some $380 million in speaking and consulting fees over a five-month period in 2013.
Some doctors received over half a million dollars each, and others got millions of dollars in royalties from products they helped develop.
Doctors claim these payments have no effect on what they prescribe. But why would drug companies shell out all this money if it didnât provide them a healthy return on their investment?
America spends a fortune on drugs, more per person than any other nation on earth, even though Americans are no healthier than the citizens of other advanced nations.
Of the estimated $2.7 trillion America spends annually on health care, drugs account for 10 percent of the total.
Government pays some of this tab through Medicare, Medicaid, and subsidies under the Affordable Care Act. But we pick up the tab indirectly through our taxes.
We pay the rest of it directly, through higher co-payments, deductibles, and premiums.
Drug company payments to doctors are a small part of a much larger strategy by Big Pharma to clean our pockets.
Another technique is called âproduct hoppingâ âmaking small and insignificant changes in a drug whose patent is about to expire, so itâs technically new.
For example, last February, before its patent expired on Namenda, its widely used drug to treat Alzheimerâs, Forest Laboratories announced it would stop selling the existing tablet form of in favor of new extended-release capsules called Namenda XR.
The capsules were just a reformulated version of the tablet. But even the minor change prevented pharmacists from substituting generic versions of the tablet.
Result: Higher profits for Forest Labs and higher costs for you and me.
Another technique is for drug companies to continue to aggressively advertise prescription brands long after their twenty-year patents have expired, so patients ask their doctors for them. Many doctors will comply.
America is one of few advanced nations that allow direct advertising of prescription drugs.
A fourth tactic is for drug companies to pay the makers of generic drugs to delay their cheaper versions. These so-called âpay-for-delayâ agreements generate big profits for both the proprietary manufacturers and the generics. But here again, you and I pay. The tactic costs us an estimated $3.5 billion a year.
Europe doesnât allow these sorts of payoffs, but theyâre legal in the United States because the major drug makers and generics have fought off any legislative attempts to stop them.
Finally, while other nations set wholesale drug prices, the law prohibits the U.S. government from using its considerable bargaining power under Medicare and Medicaid to negotiate lower drug prices. This was part of the deal Big Pharma extracted for its support of the Affordable Care Act of 2010.
The drug companies say they need the additional profits to pay for researching and developing new drugs.
But the government supplies much of the research Big Pharma relies on, through the National Institutes of Health.
Meanwhile, Big Pharma is spending more on advertising and marketing than on research and development â often tens of millions to promote a single drug.
And itâs spending hundreds of millions more every year lobbying. Last year alone, the lobbying tab came to $225 million, according to the Center for Responsive Politics.
Thatâs more than the formidable lobbying expenditures of Americaâs military contractors.
In addition, Big Pharma is spending heavily on political campaigns. In 2012, it shelled out over $36 million, making it the biggest political contributor of all American industries.
Why do we put up with this? Itâs too facile to say we have no choice given how much the industry is spending on politics. If the public were sufficiently outraged, politicians and regulatory agencies wouldnât allow this giant ripoff.
But the public isnât outraged. Thatâs partly because much of this strategy is hidden from public view.
But I think itâs also because weâve bought the ideological claptrap of the âfree marketâ being separate from and superior to government.
And since private property and freedom of contract are the core of the free market, we assume drug companies have every right to charge what they want for the property they sell.
Yet in reality the âfree marketâ canât be separated from government because government determines the rules of the game.
It determines, for example, what can be patented and for how long, what side payoffs create unlawful conflicts of interest, what basic research should be subsidized, and when government can negotiate low prices.
The critical question is not whether government should play a role in the market. Without such government decisions there would be no market, and no new drugs.
The issue is how government organizes the market. So long as big drug makers have a disproportionate say in these decisions, the rest of us pay through the nose.
Robert Reich is Chancellorâs Professor of Public Policy at the University of California at Berkeley and Senior Fellow at the Blum Center for Developing Economies. He was Secretary of Labor in the Clinton administration. Republished here under a Creative Commons License from RobertReich.org.
Before you continue, I’d like to ask if you could support our independent journalism as we head into one of the most critical news periods of our time in 2024.
The New American Journal is deeply dedicated to uncovering the escalating threats to our democracy and holding those in power accountable. With a turbulent presidential race and the possibility of an even more extreme Trump presidency on the horizon, the need for independent, credible journalism that emphasizes the importance of the upcoming election for our nation and planet has never been greater.
However, a small group of billionaire owners control a significant portion of the information that reaches the public. We are different. We don’t have a billionaire owner or shareholders. Our journalism is created to serve the public interest, not to generate profit. Unlike much of the U.S. media, which often falls into the trap of false equivalence in the name of neutrality, we strive to highlight the lies of powerful individuals and institutions, showing how misinformation and demagoguery can harm democracy.
Our journalists provide context, investigate, and bring to light the critical stories of our time, from election integrity threats to the worsening climate crisis and complex international conflicts. As a news organization with a strong voice, we offer a unique, outsider perspective that is often missing in American media.
Thanks to our unique reader-supported model, you can access the New American journal without encountering a paywall. This is possible because of readers like you. Your support keeps us independent, free from external influences, and accessible to everyone, regardless of their ability to pay for news.
Please help if you can.
American journalists need your help more than ever as forces amass against the free press and democracy itself. We must not let the crypto-fascists and the AI bots take over.
See the latest GoFundMe campaign here or click on this image.
Don't forget to listen to the new song and video.
Just because we are not featured on cable TV news talk shows, or TikTok videos, does not mean we are not getting out there in search engines and social media sites. We consistently get over a million hits a month.
Click to Advertise Here